文献速递其他结缔组织病

系统性硬化症患者自体脂肪来源血管基质组分(SVF)的分子特征与促血管生成活性

Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis.
PubMed 文献 · Ann Rheum Dis · 2019-01-05

本研究比较了24例系统性硬化症(SSc)患者与12名健康供者(HD)的自体脂肪来源血管基质组分(SVF)的分子与功能特征。结果显示SSc-SVF的细胞亚群分布与HD-SVF相似,仍保留血管生成能力,但植入裸鼠后新生血管密度略低于HD-SVF,且呈现反映血管生成失调、内皮激活和纤维化的差异分子特征。研究首次表明SSc不损害SVF的血管修复能力,支持其作为自体生物治疗的应用。

要点

  • SSc-SVF的细胞亚群分布与健康供者相似,仍保留血管生成能力。
  • SSc-SVF在裸鼠Matrigel模型中新生血管密度较HD-SVF略降低。
  • SSc-SVF呈现血管生成失调、内皮激活和纤维化相关的差异分子特征。

核心结论

  • SSc不损害自体SVF的血管修复能力,支持其作为创新性自体生物治疗的应用。
  • SSc-SVF的特异性分子谱为界定SVF效力标志物及治疗靶点提供了新视角。

研究设计与样本

  • 研究纳入24例SSc患者和12名健康供者,获取符合良好生产规范(GMP)级的SVF进行分析。
  • 采用流式细胞术比较CD45-和CD45+造血细胞亚群分布。
  • 采用体内Matrigel实验评估SVF形成血管网络的能力。
  • 采用RNA测序和多因子分析分别评估SSc-SVF的转录组和分泌谱,并与HD-SVF比较。

主要发现

  • SSc-SVF与HD-SVF的白细胞、内皮、基质、周细胞及过渡细胞亚群分布相似。
  • SSc-SVF保留血管生成能力,但植入裸鼠的SVF负载Matrigel中新生血管密度较HD-SVF略降低。
  • SSc-SVF呈现差异分子特征,反映血管生成失调、内皮激活和纤维化。

临床怎么用

  • SSc患者自体SVF仍保留血管修复能力,支持其作为自体生物治疗用于SSc相关血管病变和手部功能障碍。
  • SSc-SVF特异性分子谱可用于 delineating SVF效力标志物及治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The autologous stromal vascular fraction (SVF) from adipose tissue is an alternative to cultured adipose-derived stem cells for use in regenerative medicine and represents a promising therapy for vasculopathy and hand disability in systemic sclerosis (SSc). However, the bioactivity of autologous SVF is not documented in this disease context. This study aimed to compare the molecular and functional profiles of the SVF-based medicinal product obtained from SSc and healthy subjects. METHODS: Good manufacturing practice (GMP)-grade SVF from 24 patients with SSc and 12 healthy donors (HD) was analysed by flow cytometry to compare the distribution of the CD45- and CD45+ haematopoietic cell subsets. The ability of SVF to form a vascular network was assessed using Matrigel in vivo assay. The transcriptomic and secretory profiles of the SSc-SVF were assessed by RNA sequencing and multiplex analysis, respectively, and were compared with the HD-SVF. RESULTS: The distribution of the leucocyte, endothelial, stromal, pericyte and transitional cell subsets was similar for SSc-SVF and HD-SVF. SSc-SVF retained its vasculogenic capacity, but the density of neovessels formed in SVF-loaded Matrigel implanted in nude mice was slightly decreased compared with HD-SVF. SSc-SVF displayed a differential molecular signature reflecting deregulation of angiogenesis, endothelial activation and fibrosis. CONCLUSIONS: Our study provides the first evidence that SSc does not compromise the vascular repair capacity of SVF, supporting its use as an innovative autologous biotherapy. The characterisation of the specific SSc-SVF molecular profile provides new perspectives for delineating markers of the potency of SVF and its targets for the treatment of SSc.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Magalon J, Velier M, Simoncini S, et al. Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis. Ann Rheum Dis. 2019. PMID: 30612118. doi:10.1136/annrheumdis-2018-214218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。